HYBRID EVENT: You can participate in person at Baltimore, Maryland, USA or Virtually from your home or work.
Sean Yanik, Speaker at Vaccine Conferences
Johns Hopkins, United States
Title : Immature dendritic cell targeting mRNA vaccine enhances protection from Plasmodium liver stage infection by enhancing T cell responses and antibody titers against CSP repeat regions

Abstract:

In 2021, there were 247 million clinical cases and 619,000 deaths from malaria. RTS, S, the first and only WHO approved vaccine for malaria, targets the pre-erythrocytic stage antigen circumsporozoite protein (CSP) and provides only limited efficacy, reducing clinical malaria by a modest 30%. For RTS, S and other pre-erythrocytic stage targeting vaccines, the ability to produce a robust immune response, eliciting high antibody titers and engaging a productive T cell are the primary obstacles to achieving vaccine-induced protection. Here, we describe the creation of a novel CSP mRNA, chemokine fusion vaccine, designed to overcome these challenges. Vaccination with mRNA expressing full-length CSP fused to macrophage inflammatory protein 3 alpha (MIP3a), provided significantly greater protection against sporozoite challenge than vaccination with mRNA expressing full-length CSP alone. The CSP-MIP3a fusion vaccine enhanced antibody titers against highly neutralizing NANP repeat epitopes and stimulated both CD4+ and CD8+ T cell responses. Protection from sporozoite challenge correlated significantly with titers against NANP repeats and T cell stimulation, particularly CD4+ T cytokine responses.

What will audience learn from your presentation?

  • Mechanisms of increasing antibody titers to vaccines
  • Importance of polyfunctional T cell responses to immunogens
  • Use of chemokines for dendritic cell targeting
  • Benefits of fractional and delayed dosing in mRNA vaccines
  • Importance of the NANP repeat region in vaccines targeting circumsporozoite protein.

 

Biography:

Sean Yanik is a 6th year MD/PhD student (3rd year PhD), working in the Department of Molecular Microbiology and Immunology (MMI) at Johns Hopkins Bloomberg School of Public Health.  Sean was recently published in Nature Communications and is the head teacher/ course instructor for an undergraduate course in malaria at JH. He is currently completing his PhD in Biomedical Engineering at JHSOM. He received a B.S from the University of Michigan in Biomolecular Sciences in 2017. Sean has worked in the laboratory of Sean Yanik is a 6th year MD/PhD student (3rd year PhD), working in the Department of Molecular Microbiology and Immunology (MMI) at Johns Hopkins Bloomberg School of Public Health.  Sean was recently published in Nature Communications and is the head teacher/ course instructor for an undergraduate course in malaria at JH. He is currently completing his PhD in Biomedical Engineering at JHSOM. He received a B.S from the University of Michigan in Biomolecular Sciences in 2017. Sean has worked in the laboratory of Dr. Prakash Srinivasan in MMI since 2019, studying the development of malaria vaccines.

Watsapp